Broad and potent neutralizing antibodies from an african donor reveal a new HIV-1 vaccine target Academic Article uri icon


MeSH Major

  • AIDS Vaccines
  • Antibodies, Monoclonal
  • HIV Antibodies
  • HIV Envelope Protein gp120
  • HIV Infections
  • HIV-1


  • Broadly neutralizing antibodies (bNAbs), which develop over time in some HIV-1-infected individuals, define critical epitopes for HIV vaccine design. Using a systematic approach, we have examined neutralization breadth in the sera of about 1800 HIV-1-infected individuals, primarily infected with non-clade B viruses, and have selected donors for monoclonal antibody (mAb) generation. We then used a high-throughput neutralization screen of antibody-containing culture supernatants from about 30,000 activated memory B cells from a clade A-infected African donor to isolate two potent mAbs that target a broadly neutralizing epitope. This epitope is preferentially expressed on trimeric Envelope protein and spans conserved regions of variable loops of the gp120 subunit. The results provide a framework for the design of new vaccine candidates for the elicitation of bNAb responses.

publication date

  • October 9, 2009



  • Academic Article



  • eng

PubMed Central ID

  • PMC3335270

Digital Object Identifier (DOI)

  • 10.1126/science.1178746

PubMed ID

  • 19729618

Additional Document Info

start page

  • 285

end page

  • 9


  • 326


  • 5950